[Prognostic significance of lymphocytes forming "active rosettes" in lung cancer].
Lymphocytes forming E rosettes, active E, autologous and EA antibodies were studied in 66 subjects (56 men, 10 women, mean age 59, range: 40-85 years) who presented with lung cancer classified on the TMN scale in stages I and II: 19; stage III: 20; stage IV: 27. In comparison to the controls, there was a significant reduction (p less than 0.01) in E, autologous and EA rosettes in the patients. A reduction in E active rosettes (compared to controls) was noted for stage IV cases (p less than 0.01) and rose with the stage. The formation of rosettes was reduced in 50 squamous carcinomas compared to 12 anaplastic carcinomas for E rosettes (p less than 0.01) and E active (p less than 0.02). If one compares the actuarial survival curves of 37 patients with E act rosettes greater than or equal to 23% and of 29 with a level of less than 23%, the mean survival for all stages combined was 14.1 months in the first group and 8.2 months in the second group. Associated with an extension of the tumour, the immunological system has a role in determining outcome and lymphocytes forming active E rosettes appear to be the subpopulation most closely correlated with survival.
D000230:Adenocarcinoma / Q000276:immunology; D000328:Adult; D000368:Aged; D000708:Anaplasia / Q000276:immunology; D002294:Carcinoma, Squamous Cell / Q000276:immunology; D004912:Erythrocytes / Q000276:immunology / Q000378:metabolism; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000276:immunology* / Q000401:mortality / Q000473:pathology; D008214:Lymphocytes / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011379:Prognosis; D012397:Rosette Formation
Intérêt pronostique des lymphocytes formant des "rosettes actives" dans le cancer du poumon.